Morepen Laboratories enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


6,881	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
171	54.1	105	16.9	21.7
0.8	0.7	30.7	0.0	−0.5
195	195	79.4	29.0	25.2
6,905	—	—	—	—
23.5	141	−25.8	12.1	3.5
₹126.02	—	—	—	—

1,577	1,442	1,266	876	778
12.3%	13.5%	6.3%	3.3%	3.2%
0.03×	—	—	—	—

3.02×	—	—	—	—
24.98×	—	—	—	—
28.55×	—	—	—	—
2,286	1,806	1,812	1,690	1,418
276	126	174	159	79.5
242	89.2	145	125	51.6
—	32.6	32.1	73.4	−91.2
−128	−128	−182	−8.0	−137
—	−131	−184	−9.0	−138
—	161	214	81.3	46.0

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MOREPENLAB₹125.58

Morepen Laboratories Limited

· Pharma & Health

₹ CrorePeersIOLCP INNOVACAP FDC ORCHPHARMA SENORES SANOFI GUJTHEM RPGLIFEMcap ₹6,881 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	6,880.8
- Cash, Equiv & ST Investments	21.7	16.9	105.2	54.1	171.2
+ Minority Interest	-0.5	0.0	30.7	0.7	0.8
+ Total Debt	25.2	29.0	79.4	194.7	194.7
Enterprise Value	—	—	—	—	6,905.0
Net Debt (memo)	3.5	12.1	-25.8	140.6	23.5
EV per Share	—	—	—	—	126.02

Total Capital	777.6	876.2	1,266.4	1,441.8	1,576.6
Total Debt/Total Capital	3.24	3.31	6.27	13.50	12.35
Total Debt/EV	—	—	—	—	0.03

EV/Sales	—	—	—	—	3.02
EV/EBITDA	—	—	—	—	24.98
EV/EBIT	—	—	—	—	28.55
Reference Items — Trailing FY Values
Sales	1,417.5	1,690.4	1,811.6	1,805.7	2,285.5
EBITDA	79.5	158.6	174.1	125.6	276.4
EBIT	51.6	125.2	145.1	89.2	241.9
Operating Cash Flow	-91.2	73.4	32.1	32.6	—
Free Cash Flow	-137.1	-8.0	-182.2	-127.9	-127.9
FCFF (free cash flow to the firm)	-137.7	-9.0	-184.2	-131.2	—
Capital Expenditure	46.0	81.3	214.2	160.5	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.